Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -17.66
- Piotroski Score 4.00
- Grade Buy
- Symbol (IBIO)
- Company iBio, Inc.
- Price $2.79
- Changes Percentage (13.88%)
- Change $0.34
- Day Low $2.46
- Day High $2.79
- Year High $6.20
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/14/2025
- Fiscal Year End N/A
- Average Stock Price Target $3.60
- High Stock Price Target $3.60
- Low Stock Price Target $3.60
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$7.23
- Trailing P/E Ratio -0.33
- Forward P/E Ratio -0.33
- P/E Growth -0.33
- Net Income $-24,907,000
Income Statement
Quarterly
Annual
Latest News of IBIO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TenNor's Phase III antibiotic trial meets all primary endpoints
TenNor Therapeutics' Phase III trial of rifasutenizol for H. pylori infection successfully met primary endpoints, surpassing current treatment standards. The antibiotic showed high efficacy, safety, a...
By Yahoo! Finance | 3 days ago -
Paratek's antibiotic succeeds in Phase IIb lung disease trial
Paratek Pharmaceuticals reports positive Phase IIb trial results for oral antibiotic Nuzyra in treating NTM pulmonary disease. The therapy shows improvement in symptoms with favorable trends observed....
By Yahoo! Finance | 1 week ago -
UK supermarkets not doing enough to tackle antibiotic misuse, report says
UK supermarkets are failing to ensure responsible antibiotic use in their farm animal suppliers, despite the rising threat of superbugs. Stricter enforcement is needed to combat overuse of antibiotics...
By The Guardian | 1 month ago
